NCT00060411View on ClinicalTrials.gov

A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

July 31, 2007

Conditions
Mucinous Adenocarcinoma of the ColonMucinous Adenocarcinoma of the RectumRecurrent Colon CancerRecurrent Rectal CancerSignet Ring Adenocarcinoma of the ColonSignet Ring Adenocarcinoma of the RectumStage IIIA Colon CancerStage IIIA Rectal CancerStage IIIB Colon CancerStage IIIB Rectal CancerStage IIIC Colon CancerStage IIIC Rectal CancerStage IVA Colon CancerStage IVA Rectal CancerStage IVB Colon CancerStage IVB Rectal Cancer
Interventions
DRUG

erlotinib hydrochloride

Given IV

DRUG

fluorouracil

Given IV

DRUG

leucovorin calcium

Given IV

DRUG

oxaliplatin

Given IV

BIOLOGICAL

bevacizumab

Given IV

Trial Locations (1)

21287-8936

Johns Hopkins University, Baltimore

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00060411 - A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer | Biotech Hunter | Biotech Hunter